Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor
prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately …

Patients with small cell lung cancer (SCLC) generally have a poor prognosis and a median
overall survival of only about 13 months, indicating the urgent need for novel therapies …

Small cell lung cancer (SCLC) is a highly aggressive and poorly differentiated cancer with
high-grade neuroendocrine (NE) features, accounting for approximately 15% of all lung …

Simple Summary Small cell lung cancer (SCLC) remains a difficult-to-treat disease and is
associated with a poor prognosis in most patients. Discovering biomarkers and developing …

The current review elucidates the characteristics and related regulating pathways of lung
CSCs from essential to preclinical research. We retrospectively introduce an update on the …

Small cell lung cancer (SCLC) is a rapidly progressive neuroendocrine carcinoma that, until
recently, had a very small armamentarium of effective treatments. Advances in DNA …

Small-cell lung cancer (SCLC) is an aggressive, neuroendocrine tumour with high relapse
rates, and significant morbidity and mortality. Apart from advances in radiation therapy …

Small cell lung cancer (SCLC) constitutes approximately 10% to 15% of all lung cancer
diagnoses and represents a pressing global public health challenge due to its high mortality …

Small-cell lung cancer (SCLC) comprises approximately 14% of all lung cancer diagnoses
and is exceptionally lethal. Approximately two thirds of patients with SCLC present with extra …